<?xml version="1.0" encoding="UTF-8"?>
<TEI xml:space="preserve" xmlns="http://www.tei-c.org/ns/1.0"
xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
xsi:schemaLocation="http://www.tei-c.org/ns/1.0 https://raw.githubusercontent.com/kermitt2/grobid/master/grobid-home/schemas/xsd/Grobid.xsd"
 xmlns:xlink="http://www.w3.org/1999/xlink">
	<teiHeader xml:lang="en">
		<fileDesc>
			<titleStmt>
				<title level="a" type="main" xml:id="_2xcvMmk">Eff ects of a mobile phone short message service on antiretroviral treatment adherence in Kenya (WelTel Kenya1): a randomised trial</title>
				<funder ref="#_rV8NxR3">
					<orgName type="full">Government of Kenya Ministry of Health</orgName>
				</funder>
				<funder>
					<orgName type="full">University of Manitoba</orgName>
					<orgName type="abbreviated">UM</orgName>
					<idno type="DOI" subtype="crossref">https://doi.org/10.13039/100010318</idno>
				</funder>
				<funder>
					<orgName type="full">US President&apos;s Emergency Plan for AIDS Relief (PEPFAR)</orgName>
				</funder>
				<funder>
					<orgName type="full">Canadian Institutes of Health Research</orgName>
					<orgName type="abbreviated">IRSC</orgName>
					<idno type="DOI" subtype="crossref">https://doi.org/10.13039/501100000024</idno>
				</funder>
				<funder>
					<orgName type="full">PEPFAR</orgName>
				</funder>
				<funder ref="#_wCDzPxu">
					<orgName type="full">Coptic Hope Center for Infectious Diseases</orgName>
				</funder>
				<funder ref="#_JSuFB8g">
					<orgName type="full">CDC cooperative agreement</orgName>
				</funder>
				<funder>
					<orgName type="full">CIHR/ICID (International Center for Infectious Diseases) National Training Program in Infectious Diseases</orgName>
				</funder>
				<funder ref="#_xeTffuG">
					<orgName type="full">CDC</orgName>
				</funder>
				<funder ref="#_yNNhV8Y">
					<orgName type="full">National Institutes of Health</orgName>
					<orgName type="abbreviated">NIH</orgName>
					<idno type="DOI" subtype="crossref">https://doi.org/10.13039/100000002</idno>
				</funder>
				<funder>
					<orgName type="full">Association of Medical Microbiology and Infectious Diseases-Bristol-Myers-Squibb (Canada)</orgName>
				</funder>
			</titleStmt>
			<publicationStmt>
				<publisher/>
				<availability  status="unknown">
					<licence/>
				</availability>
				<date type="published" when="2010-11-09">November 9, 2010</date>
			</publicationStmt>
			<sourceDesc>
				<biblStruct>
					<analytic>
						<author role="corresp">
							<persName><roleName>MD, A Kariri BSc, S Karanja BSc</roleName><forename type="first">Richard</forename><forename type="middle">T</forename><surname>Lester</surname></persName>
							<email>rlester.id@gmail.com</email>
							<affiliation key="aff8">
								<note type="raw_affiliation"><label>B</label> University of Nairobi Institute of Tropical and Infectious Diseases , Nairobi , Kenya ( Estambale MBChB) ;</note>
								<orgName type="department">Estambale MBChB)</orgName>
								<orgName type="institution">University of Nairobi Institute of Tropical and Infectious Diseases</orgName>
								<address>
									<settlement>Nairobi</settlement>
									<country key="KE">Kenya</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><roleName>PhD</roleName><forename type="first">Elizabeth</forename><surname>Ngugi</surname></persName>
						</author>
						<author>
							<persName><roleName>MD</roleName><forename type="first">Lawrence</forename><forename type="middle">J</forename><surname>Gelmon</surname></persName>
						</author>
						<author>
							<persName><roleName>Prof F A Plummer MD</roleName><forename type="first">Joshua</forename><surname>Kimani</surname></persName>
						</author>
						<author>
							<persName><roleName>PhD</roleName><forename type="first">T</forename><forename type="middle">B</forename><surname>Ball</surname></persName>
						</author>
						<author>
							<persName><roleName>MD</roleName><forename type="first">Mohsen</forename><surname>Sadatsafavi</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Najafzadeh</forename><surname>Msc</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Marra</forename><surname>Pharmd</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Paul</forename><surname>Ritvo</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Edward</forename><forename type="middle">J</forename><surname>Mills</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Antony</forename><surname>Kariri</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Sarah</forename><surname>Karanja</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Michael</forename><forename type="middle">H</forename><surname>Chung</surname></persName>
						</author>
						<author>
							<persName><forename type="first">William</forename><surname>Jack</surname></persName>
						</author>
						<author>
							<persName><forename type="first">James</forename><surname>Habyarimana</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Mehdi</forename><surname>Najafzadeh</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Carlo</forename><forename type="middle">A</forename><surname>Marra</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Benson</forename><surname>Estambale</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Blake</forename><surname>Ball</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Lehana</forename><surname>Thabane</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Marta</forename><surname>Ackers</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Francis</forename><forename type="middle">A</forename><surname>Plummer</surname></persName>
						</author>
						<author>
							<affiliation key="aff0">
								<note type="raw_affiliation">Department of Medical Microbiology , University of Nairobi , Nairobi , Kenya</note>
								<orgName type="department">Department of Medical Microbiology</orgName>
								<orgName type="institution">University of Nairobi</orgName>
								<address>
									<settlement>Nairobi</settlement>
									<country key="KE">Kenya</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff1">
								<note type="raw_affiliation">Department of Medical Microbiology , University of Manitoba , Health Sciences Centre , Winnipeg , MB , Canada</note>
								<orgName type="department" key="dep1">Department of Medical Microbiology</orgName>
								<orgName type="department" key="dep2">Health Sciences Centre</orgName>
								<orgName type="institution">University of Manitoba</orgName>
								<address>
									<settlement>Winnipeg</settlement>
									<region>MB</region>
									<country key="CA">Canada</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff2">
								<note type="raw_affiliation">Division of Infectious Diseases , Department of Medicine , University of British Columbia , Vancouver , BC , Canada (R</note>
								<orgName type="department" key="dep1">Division of Infectious Diseases</orgName>
								<orgName type="department" key="dep2">Department of Medicine</orgName>
								<orgName type="institution">University of British Columbia</orgName>
								<address>
									<settlement>Vancouver</settlement>
									<region>BC</region>
									<country>Canada (R</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff3">
								<note type="raw_affiliation"><label>P</label> T Lester) ; School of Kinesiology and Health Sciences , Department of Psychology , York University , York , ON , Canada (</note>
								<orgName type="department" key="dep1">T Lester)</orgName>
								<orgName type="department" key="dep2">School of Kinesiology and Health Sciences</orgName>
								<orgName type="department" key="dep3">Department of Psychology</orgName>
								<orgName type="institution">York University</orgName>
								<address>
									<settlement>York</settlement>
									<region>ON</region>
									<country key="CA">Canada</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff4">
								<note type="raw_affiliation">Ritvo PhD) ; Faculty of Health Sciences , University of Ottawa , Ottawa , ON , Canada (E J</note>
								<orgName type="department" key="dep1">Ritvo PhD)</orgName>
								<orgName type="department" key="dep2">Faculty of Health Sciences</orgName>
								<orgName type="institution">University of Ottawa</orgName>
								<address>
									<settlement>Ottawa</settlement>
									<region>ON (E J</region>
									<country key="CA">Canada</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff5">
								<note type="raw_affiliation">Mills PhD) ; Department of Global Health , University of Washington , Seattle , WA , USA (M H</note>
								<orgName type="department" key="dep1">Mills PhD)</orgName>
								<orgName type="department" key="dep2">Department of Global Health</orgName>
								<orgName type="institution">University of Washington</orgName>
								<address>
									<settlement>Seattle</settlement>
									<region>WA (M H</region>
									<country key="US">USA</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff6">
								<note type="raw_affiliation">Chung MD) ; Department of Economics (W Jack DPhil) and Georgetown Public Policy Institute (J Habyarimana PhD) , Georgetown University , Washington , DC , USA; Collaboration for Outcome Research and Evaluation ,</note>
								<orgName type="department" key="dep1">Chung MD)</orgName>
								<orgName type="department" key="dep2">Department of Economics (W Jack DPhil)</orgName>
								<orgName type="department" key="dep3">J Habyarimana PhD</orgName>
								<orgName type="laboratory">Collaboration for Outcome Research and Evaluation</orgName>
								<orgName type="institution" key="instit1">Georgetown Public Policy Institute</orgName>
								<orgName type="institution" key="instit2">Georgetown University</orgName>
								<address>
									<settlement>Washington</settlement>
									<region>DC</region>
									<country>USA;</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff7">
								<note type="raw_affiliation">Faculty of Pharmaceutical Sciences , University of British Columbia , Vancouver , BC , Canada</note>
								<orgName type="department">Faculty of Pharmaceutical Sciences</orgName>
								<orgName type="institution">University of British Columbia</orgName>
								<address>
									<settlement>Vancouver</settlement>
									<region>BC</region>
									<country key="CA">Canada</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff9">
								<note type="raw_affiliation">Department of Clinical Epidemiology and Biostatistics , McMaster University , Hamilton , ON , Canada</note>
								<orgName type="department">Department of Clinical Epidemiology and Biostatistics</orgName>
								<orgName type="institution">McMaster University</orgName>
								<address>
									<settlement>Hamilton</settlement>
									<region>ON</region>
									<country key="CA">Canada</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff10">
								<note type="raw_affiliation">Emergency Plan for AIDS Relief. Global AIDS Program , US Centers for Disease Control and Prevention , Nairobi , Kenya (M</note>
								<orgName type="department">Emergency Plan for AIDS Relief. Global AIDS Program</orgName>
								<orgName type="institution">US Centers for Disease Control and Prevention</orgName>
								<address>
									<settlement>Nairobi</settlement>
									<region>M</region>
									<country key="KE">Kenya</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff11">
								<note type="raw_affiliation">Ackers MD) ; and National Microbiology Laboratory , Public Health Agency of Canada , Winnipeg , MB , Canada</note>
								<orgName type="department">Ackers MD)</orgName>
								<orgName type="institution" key="instit1">National Microbiology Laboratory</orgName>
								<orgName type="institution" key="instit2">Public Health Agency of Canada</orgName>
								<address>
									<settlement>Winnipeg</settlement>
									<region>MB</region>
									<country key="CA">Canada</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff12">
								<note type="raw_affiliation">British Columbia Centre for Disease Control , 655 West 12th Avenue , Vancouver , BC , V5Z 4R4 , Canada</note>
								<orgName type="institution">British Columbia Centre for Disease Control</orgName>
								<address>
									<addrLine>655 West 12th Avenue</addrLine>
									<postCode>V5Z 4R4</postCode>
									<settlement>Vancouver</settlement>
									<region>BC</region>
									<country key="CA">Canada</country>
								</address>
							</affiliation>
						</author>
						<title level="a" type="main" xml:id="_GhmN5uk">Eff ects of a mobile phone short message service on antiretroviral treatment adherence in Kenya (WelTel Kenya1): a randomised trial</title>
					</analytic>
					<monogr>
						<imprint>
							<date type="published" when="2010-11-09">November 9, 2010</date>
						</imprint>
					</monogr>
					<idno type="MD5">C7C6FC53E699FC74EEF8479B4E041951</idno>
					<idno type="DOI">10.1016/S0140-</idno>
				</biblStruct>
			</sourceDesc>
		</fileDesc>
		<encodingDesc>
			<appInfo>
				<application version="0.8.2" ident="GROBID" when="2025-08-31T07:36+0000">
					<desc>GROBID - A machine learning software for extracting information from scholarly documents</desc>
					<label type="revision">a91ee48</label>
					<label type="parameters">startPage=-1, endPage=-1, consolidateCitations=2, consolidateHeader=2, consolidateFunders=1, includeRawAffiliations=true, includeRawCitations=true, includeRawCopyrights=true, generateTeiIds=true, generateTeiCoordinates=[all], sentenceSegmentation=true, flavor=null</label>
					<ref target="https://github.com/kermitt2/grobid"/>
				</application>
			</appInfo>
		</encodingDesc>
		<profileDesc>
			<abstract>
<div xmlns="http://www.tei-c.org/ns/1.0" xml:id="_dhjtn9N"><p xml:id="_cKTskvc"><s xml:id="_vKtYhKt">Background Mobile (cell) phone communication has been suggested as a method to improve delivery of health services.</s><s xml:id="_EP8EY3W">However, data on the eff ects of mobile health technology on patient outcomes in resource-limited settings are limited.</s><s xml:id="_cdAe28v">We aimed to assess whether mobile phone communication between health-care workers and patients starting antiretroviral therapy in Kenya improved drug adherence and suppression of plasma HIV-1 RNA load.</s></p><p xml:id="_3aurWe6"><s xml:id="_bFqxhwV">Methods WelTel Kenya1 was a multisite randomised clinical trial of HIV-infected adults initiating antiretroviral therapy (ART) in three clinics in Kenya.</s><s xml:id="_PxjWGt2">Patients were randomised (1:1) by simple randomisation with a random number generating program to a mobile phone short message service (SMS) intervention or standard care.</s><s xml:id="_FTJcsm3">Patients in the intervention group received weekly SMS messages from a clinic nurse and were required to respond within 48 h.</s><s xml:id="_PPthMuh">Randomisation, laboratory assays, and analyses were done by investigators masked to treatment allocation; however, study participants and clinic staff were not masked to treatment.</s><s xml:id="_4deXfm7">Primary outcomes were self-reported ART adherence (&gt;95% of prescribed doses in the past 30 days at both 6 and 12 month follow-up visits) and plasma HIV-1 viral RNA load suppression (&lt;400 copies per mL) at 12 months.</s><s xml:id="_gJJXqv4">The primary analysis was by intention to treat.</s><s xml:id="_tZBF92V">This trial is registered with ClinicalTrials.gov,</s><s xml:id="_ZcgNmY2">NCT00830622.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_PQwKcDG">Findings</head><p xml:id="_TmKsrfe"><s xml:id="_mX28K3M">Between May, 2007, and October, 2008, we randomly assigned 538 participants to the SMS intervention (n=273) or to standard care (n=265).</s><s xml:id="_tzBDXjs">Adherence to ART was reported in 168 of 273 patients receiving the SMS intervention compared with 132 of 265 in the control group (relative risk [RR] for non-adherence 0•81, 95% CI 0•69-0•94; p=0•006).</s><s xml:id="_Mk488uz">Suppressed viral loads were reported in 156 of 273 patients in the SMS group and 128 of 265 in the control group, (RR for virologic failure 0•84, 95% CI 0•71-0•99; p=0•04).</s><s xml:id="_FSqAPX4">The number needed to treat (NNT) to achieve greater than 95% adherence was nine (95% CI 5•0-29•5) and the NNT to achieve viral load suppression was 11 (5•8-227•3).</s><s xml:id="_6MQKTu4">Interpretation Patients who received SMS support had signifi cantly improved ART adherence and rates of viral suppression compared with the control individuals.</s><s xml:id="_qsHgA4f">Mobile phones might be eff ective tools to improve patient outcome in resource-limited settings.</s></p></div>
			</abstract>
		</profileDesc>
	</teiHeader>
	<facsimile>
		<surface n="1" ulx="0.0" uly="0.0" lrx="595.276" lry="799.37"/>
		<surface n="2" ulx="0.0" uly="0.0" lrx="595.276" lry="799.37"/>
		<surface n="3" ulx="0.0" uly="0.0" lrx="595.276" lry="799.37"/>
		<surface n="4" ulx="0.0" uly="0.0" lrx="595.276" lry="799.37"/>
		<surface n="5" ulx="0.0" uly="0.0" lrx="595.276" lry="799.37"/>
		<surface n="6" ulx="0.0" uly="0.0" lrx="595.276" lry="799.37"/>
		<surface n="7" ulx="0.0" uly="0.0" lrx="595.276" lry="799.37"/>
		<surface n="8" ulx="0.0" uly="0.0" lrx="595.276" lry="799.37"/>
	</facsimile>
	<text xml:lang="en">
		<body>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_Ra33Ud4">Introduction</head><p xml:id="_k8kSqet"><s xml:id="_kx6XUR4">Health programmes that use mobile communication technologies are emerging with the aim of strengthening health systems. <ref type="bibr" target="#b0">[1]</ref><ref type="bibr">[2]</ref></s><s xml:id="_xPbXuMW">2]<ref type="bibr" target="#b2">[3]</ref> The United Nations Joint Programme on HIV/AIDS (UNAIDS) and WHO have added wireless communication technologies to their strategic plans. <ref type="bibr" target="#b3">4,</ref><ref type="bibr" target="#b4">5</ref></s><s xml:id="_s4KSfAK">However, at present no published clinical trial has reported the use of mobile health technologies to improve patient-centred outcomes in developing countries.</s></p><p xml:id="_XgU8X4B"><s xml:id="_SNDMjQc">Present eff orts to control the HIV/AIDS pandemic include treatment with antiretroviral therapy (ART), targeted prevention strategies, and treatment as prevention measures (ie, prevention of HIV spread by treating HIV positive people and thereby reducing the risk of onward transmission). <ref type="bibr" target="#b5">6,</ref><ref type="bibr" target="#b6">7</ref></s><s xml:id="_CGrxPKJ">However, widespread progress at controlling the pandemic is restricted by poor infrastructure and increasing health-system costs.</s></p><p xml:id="_azZrUZp"><s xml:id="_bjAnADn">The number of mobile (cell) phone users is rapidly expanding (4•5 billion mobile phone subscribers are expected worldwide by 2012), <ref type="bibr" target="#b7">8</ref> mainly because of free market forces (ie, capitalism) and the demand for rapid wireless communications for personal use and to aid multi-sector economic development (eg, trade, tourism, and infrastructure); thus, mobile technology has the potential to be used in health systems worldwide.</s><s xml:id="_C87kknt">A wide range of medical services could be improved by providing patient-focused support and management through the health-care system.</s></p><p xml:id="_25Ns5qq"><s xml:id="_VHVCD3Z">Maximum adherence to ART in patients with HIV improves health outcomes and prevents drug resistance. <ref type="bibr" target="#b9">9</ref></s><s xml:id="_A2hgDqF">dherence is also important for programme cost containment. <ref type="bibr" target="#b10">10</ref></s><s xml:id="_eUMyXyv">If mobile phone use does improve health outcomes in resource-limited settings, this mobile health technology could thus be included in health-system strategies and help improve health development goals. <ref type="bibr" target="#b11">11</ref></s><s xml:id="_FDzEjTk">n this trial, we aimed to assess whether mobile phone communication between health-care workers and patients initiating ART in Kenya 2, <ref type="bibr" target="#b12">12</ref> improved drug adherence and suppression of plasma HIV-1 RNA load.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_2Ptba79">Methods</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_rXhRtpT">Patients</head><p xml:id="_6BKZQrR"><s xml:id="_T8umTAw">Patients initiating ART were recruited from three diff erent HIV clinics that are involved in intense ART provision scale-up.</s><s xml:id="_T6zFCc7">The University of Nairobi Pumwani Clinic serves a very low-income population in Nairobi <ref type="bibr" target="#b13">13</ref> and the Coptic Hope Center for Infectious Diseases operates out of a faith-based hospital located in a higherincome area of Nairobi. <ref type="bibr" target="#b14">14</ref></s><s xml:id="_QCU9RVX">The Kajiado Clinic is a government health centre in a large rural district.</s><s xml:id="_BTYQBq3">We chose these three locations because they should represent the regional diversity of health settings.</s></p><p xml:id="_JPxjFGj"><s xml:id="_TwPMqhs">Patients were eligible for study participation if they were over 18 years old, initiating ART for the fi rst time, and able to access a mobile phone on a near-daily basis and communicate via short message service (SMS).</s><s xml:id="_YJEnyek">People who did not own mobile phones were eligible if they had shared access (with corroborative agreement by the phone owner), and illiterate patients were eligible if assisted by a literate partner.</s><s xml:id="_vx5jtja">Participants used existing mobile phone services; phones and network airtime credit were not provided.</s></p><p xml:id="_st26AvJ"><s xml:id="_UHY76fF">Patients provided written or verbal informed consent at enrolment in a language they understood.</s><s xml:id="_yaK3j6s">The study protocol was approved by the University of Manitoba and Kenyatta National Hospital ethics review boards.</s></p><p xml:id="_wfu3NX3"><s xml:id="_TnrgKSP">This trial is registered with ClinicalTrials.gov,</s><s xml:id="_fdceErE">NCT00830622.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_ExaJCDk">Randomisation and masking</head><p xml:id="_puuKRXd"><s xml:id="_jBm39EB">WelTel Kenya1 was an individually randomised, parallel, multisite controlled trial.</s><s xml:id="_yhSqrWJ">Patients were randomly assigned (1:1) by simple randomisation <ref type="bibr" target="#b15">15</ref> to the SMS intervention or to standard care (control group).</s><s xml:id="_4GbNT3J">A project statistician generated the randomisation numbers with a random number generating program.</s><s xml:id="_N4Bzn6s">Written allocation of assignment was sealed in individual opaque envelopes marked with study identifi cation numbers, which were distributed to all three study clinics.</s><s xml:id="_M8f7QgS">Target enrolment was estimated at a ratio of about 2:2:1 across clinics, with the urban centres having the higher enrolment.</s><s xml:id="_tvg2m6w">We did not do block randomisation because of the unpredictable scale-up rates at each clinic.</s><s xml:id="_E2heb5A">Randomisation, laboratory assays, and analyses were done by investi gators masked to treatment allocation; however, study participants and clinic staff could not be masked because the intervention required overt participation.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_PjjCDtz">Procedures</head><p xml:id="_dA7fdMk"><s xml:id="_ZavA326">Antiretroviral drugs were provided by the government of Kenya with support from the US President's Emergency Plan for AIDS Relief (PEPFAR), and consisted primarily of three drug combinations containing zidovudine or stavudine, plus lamivudine, plus efavirenz or nevirapine as fi rst-line drugs.</s><s xml:id="_cg9dHce">Initiation of ART was in accordance with national guidelines (CD4 count &lt;250 cells per μL or WHO stage III or IV). <ref type="bibr" target="#b16">16</ref></s><s xml:id="_tcnJ6Br">ypically, the study site in Kajiado provided one counselling session at ART initiation and the two sites in Nairobi provided two counselling sessions before and one session 1 month after ART initiation.</s><s xml:id="_hPpW8UW">Disclosure of HIV status, pairing up with a treatment adherence partner, and participation in support groups was encouraged but not insisted upon.</s><s xml:id="_DQq8kPP">Additional brief counselling was provided at each site during dispensation of the drugs in the clinic or pharmacy.</s></p><p xml:id="_4bswNe9"><s xml:id="_JzZESB8">We thought that regular, structured mobile phone communication between health-care workers and patients could improve patient outcomes by both reminding patients to take their ART and by providing support to the patients.</s><s xml:id="_NFAGR5c">The intervention was planned in consultation with investigators, clinic staff , and patients (in unstructured focus group sessions) with the goals of low cost and widespread usability. <ref type="bibr">2,</ref><ref type="bibr" target="#b17">17</ref></s><s xml:id="_EBauGym">ll intervention participants received brief training for use of the SMS intervention from the study clinicians.</s><s xml:id="_9c9MhXe">They were informed that the SMS support service did not replace existing adherence counselling or emergency services.</s><s xml:id="_qqYxt7P">On Monday morning of each week, the site nurse or clinical offi cer sent a text message via SMS to patients in the intervention group to inquire about their status and thus to remind them about the availability of phone-based support.</s><s xml:id="_qhWkmqg">Typically, the slogan "Mambo?" was sent, which is Kiswahili for "How are you?"</s><s xml:id="_eNB5AkA">The health workers used multiple recipient (bulk) messaging functions to improve effi ciency.</s><s xml:id="_5q2FGmK">Patients in the intervention group were instructed to respond within 48 h that either they were doing well ("Sawa") or that they had</s></p><p xml:id="_BSSBMBW"><s xml:id="_cnmAgY7">581 patients enrolled 538 randomised 43 ineligible 39 had inadequate phone access 4 declined participation 273 assigned to SMS intervention 265 assigned to standard care 273 included in primary analysis 265 included in primary analysis 7 withdrew 3 withdrew a problem ("Shida").</s><s xml:id="_asavdpT">The clinician then called patients who said they had a problem or who failed to respond within 2 days.</s><s xml:id="_AJ7nPuV">Participants were instructed that healthcare workers were available to respond during clinic hours only.</s><s xml:id="_yW5YHXV">All mobile phone communications between the health-care workers and patients were recorded in the study log.</s><s xml:id="_dha4Se4">The primary outcomes were self-reported adherence and suppression of plasma HIV-1 viral load.</s><s xml:id="_6SzdyzW">Self-reported adherence is the most practical method of assessing adherence because it closely represents the regional standard care; <ref type="bibr" target="#b18">18</ref> however, this method of assessment has been reported to be an overestimate of adherence. <ref type="bibr" target="#b19">19</ref></s><s xml:id="_D85JeUE">At 6 and 12 months follow-up, we asked participants how many pills they missed in the past 30 days; they were classed as adherent if they reported that they had taken more than 95% of the provided pills at both follow-up visits. <ref type="bibr" target="#b9">9</ref></s><s xml:id="_CFTh6rA">We measured adherence at two timepoints to assess the durability of adherence and to increase the sensitivity to detect adherence failures, because of the high levels of adherence rates recorded by self-report regionally.</s></p><p xml:id="_UYXp9Nz"><s xml:id="_6PMT4Dk">Viral load is an important composite endpoint for monitoring adherence and takes into account pharmacological, biological, and sociobehavioural factors.</s><s xml:id="_hjXunhE">Participants were classed as virologically suppressed if their plasma HIV-1 RNA load at their 12-month visit was 400 copies per mL or less.</s><s xml:id="_y3TJdBD">Patients who did not achieve this outcome were classed as virologic failures.</s><s xml:id="_Zce6YWW">Plasma was taken from patients at the 12-month visit for assessment of HIV-1 RNA viral load (Amplicor, Roche Diagnostics, Mannheim, Germany) and was stored and analysed at a later timepoint in batches.</s><s xml:id="_aGbJVcD">Laboratory assays (CD4 count and HIV-1 RNA load) were all done at a central laboratory (University of Nairobi Institutes for Tropical and Infectious Diseases).</s><s xml:id="_Asn6Fn2">CD4 count testing (FACScan, Becton Dickinson, Sunnyvale, CA, USA) was part of routine care at the urban sites and was provided for study purposes at the rural site.</s></p><p xml:id="_dv69xN8"><s xml:id="_pwGrDmH">Secondary outcomes included the rate of attrition (not having a fi nal visit at 12 months) and rates of several categories of attrition (mortality, withdrawal from the study, transfer to non-study clinics, and loss to follow-up without identifi able cause).</s><s xml:id="_V9JXEcy">Other predefi ned secondary endpoints, including quality of life and social and economic outcomes, will be reported separately.</s><s xml:id="_UqmRknW">We also assessed the eff ects of the SMS intervention in prespecifi ed subgroups of patients subdivided by sex, urban or rural residence, clinic attended, disease stage, and whether they owned or shared a phone. <ref type="bibr" target="#b20">20</ref></s><s xml:id="_VWqcfTR">Finally, at one urban site and the rural site we ran semistructured focus group sessions with ten to 20 participants before, during, and after the start of the trial and asked for participant feedback. <ref type="bibr" target="#b20">20</ref></s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_ePTMARR">Statistical analysis</head><p xml:id="_vTYgDAu"><s xml:id="_5Gs6Tjf">We calculated that a sample size of at least 534 would be required to detect a 10% improvement in adherence, with 80% power and 0•05 level of signifi cance. <ref type="bibr" target="#b20">20,</ref><ref type="bibr" target="#b21">21</ref></s><s xml:id="_TgNPfsj">Demographic and covariate information were recorded at baseline (month 0) and at scheduled visits at 6 and 12 months.</s><s xml:id="_swmCdJy">Selfreported adherence to ART was assessed by a standardised questionnaire at each follow-up visit.</s><s xml:id="_vvV9TNA">Study staff maintained a study register to record all SMS responses and other mobile phone communications with patients.</s><s xml:id="_pPRfNAP">Patients defi ned as lost to follow-up were those unable to be traced within 3 months of the study end date.</s></p><p xml:id="_W3eGg2t"><s xml:id="_4DjQW2s">Detailed description of the analysis methods can be found in the trial protocol. <ref type="bibr" target="#b20">20</ref></s><s xml:id="_P7wf8dp">Briefl y, we analysed the SMS group (n=273) Control group (n=265) Women 177 (65%) 174 (66%) Age (years) 36•7 (8•5, 19•0-65•0) 36•6 (7•9, 22•0-84•0) Clinic University of Nairobi Pumwani Clinic 120 (44%) 131 (49%) Coptic Hope Centre for Infectious Diseases 117 (43%) 92 (35%) Kajiado Clinic 36 (13%) 42 (16%) CD4 cell count per μL* 167•6 (121•7, 2•0-887•0) 160•9 (141•4, 1•0-1522•0) WHO stage † 1 52 (23%) 62 (26%) 2 67 (29%) 59 (25%) 3 101 (44%) 103 (43%) 4 9 (4%) 13 (5%) HIV-1 plasma RNA load (log 10 copies per mL) ‡ 4•59 (1•05) 4•83 (0•96) Language literacy ¶ English only 1 (0%) 2 (1%) Kiswahili only 48 (18%) 36 (14%) Both 213 (79%) 215 (81%) Other only 9 (3%) 12 (5%) Education None 10 (4%) 14 (5%) Primary 108 (40%) 86 (32%) Secondary 106 (39%) 124 (47%) Post-secondary 49 (18%) 41 (16%) Monthly income § &lt;2000 KES (&lt;US$1/day) 72 (29%) 64 (28%) &lt;2000-10 000 KES ($1-5/day) 114 (47%) 98 (43%) 10 000-40 000 KES ($5-20/day) 46 (19%) 61 (27%) &gt;40 000 KES (&gt;$20/day) 13 (5%) 7 (3%) Mobile phone access Owns 239 (88%) 225 (85%) Shares 34 (12%) 40 (15%) Residence status Rural 51 (19%) 50 (19%) Urban 222 (81%) 215 (81%) Data are number (%), mean (SD, range), median (IQR), mean (SD).</s><s xml:id="_GmAM8rw">Percentages do not add up to 100% in some cases because of rounding.</s><s xml:id="_zDSUMHK">KES=Kenyan shillings.</s><s xml:id="_Hh8y5qF">*Data missing for one patient in the SMS group and four in the control group.</s><s xml:id="_TKebDqs">†Data missing for 44 patients in the SMS group and 28 in the control group.</s><s xml:id="_rSdryCx">‡Data missing for 21 patients in the SMS group and 25 in the control group; for 19 patients in the SMS group and ten in the control group, baseline viral load was below the limit of detection (400 copies per mL).</s><s xml:id="_KZyqz9F">Log of viral load for these patients was given as log 10 (400).</s><s xml:id="_yjfNYJX">¶Data missing for two patients in the SMS group.</s><s xml:id="_DSXXtXJ">§Data unavailable for 28 patients in the SMS group and 35 in the control group.</s></p><p xml:id="_apXYbCS"><s xml:id="_mec8Y3E">Table 1: Demographics and baseline characteristics</s></p><p xml:id="_PH8dAwd"><s xml:id="_27XDBtb">primary outcomes with the χ² test.</s><s xml:id="_ttP8ANW">The analysis of primary outcomes was by intention to treat.</s><s xml:id="_fuVfmpw">The primary analyses were not adjusted, as prespecifi ed and recommended. <ref type="bibr" target="#b20">20,</ref><ref type="bibr" target="#b22">22</ref></s><s xml:id="_Fts2X7u">elative risk (RR) was reported for non-adherence and virologic failure, with an RR less than 1 suggesting better outcome for the intervention group.</s><s xml:id="_Gb59PMh">As a measure of absolute eff ect size, we also calculated the number needed to treat (NNT) and its associated 95% CI for both unadjusted primary outcomes. <ref type="bibr" target="#b23">23</ref></s><s xml:id="_TeNbPmv">We also did a per-protocol (complete-case) analysis of the primary outcomes, in which only participants who had complete primary outcome data (self-reported adherence at 6 and 12 months and viral load at 12 months) were included.</s><s xml:id="_YkzKrzF">We also did adjusted analyses by fi tting a logistic regression model to the primary outcomes with adjustments for sex, age, baseline viral load, baseline CD4 count, and baseline WHO stage.</s><s xml:id="_mHdJs39">We used multiple imputation (PROC MI and MIANALYZE in SAS, with fi ve sets of imputations) to impute the missing values of covariates.</s></p><p xml:id="_BEUn5AV"><s xml:id="_YEyeZMY">Secondary outcomes were compared with the χ² test.</s><s xml:id="_JwgPECP">We used the Fisher's exact test for outcomes that were reported in fi ve patients or less to estimate p values.</s><s xml:id="_ADjYx3U">In the subgroup analysis in the intention-to-treat population, we compared the intervention groups within each subgroup of patients with the χ² test.</s><s xml:id="_PcYKNUj">Heterogeneity of the eff ect of the intervention across subgroups was assessed by comparing logistic regression models with and without interaction term between treatment allocation and subgroup-defi ning variables (using the likelihood-ratio test).</s></p><p xml:id="_SE4DgJK"><s xml:id="_dbS9cr5">The criterion for signifi cance was set at α=0•05.</s><s xml:id="_BdCjsFw">Bonferroni correction with resulting p values of 0•01 (for fi ve tests) was used for predefi ned exploratory secondary and subgroup analyses.</s><s xml:id="_q5Ct2sn">For all models, the results are expressed as an estimate of eff ect size, with 95% CIs and p values.</s><s xml:id="_SQDDR5v">The response type throughout the study period was analysed by categorising time since random allocation to the fi rst 3 months and afterwards, and doing a χ² test between time and response type.</s><s xml:id="_qr3DEyE">All statistical analyses were done with SAS (version 9.2, 64-bit edition).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_z5HtNpG">Role of the funding source</head><p xml:id="_GgWynKe"><s xml:id="_E9gcRVH">The sponsors of the study had no role in the design of the original study protocol, data collection, data analysis, data interpretation, writing of the report, or decision to submit the manuscript for publication.</s><s xml:id="_EywPB7U">RTL, TK, SK, MHC, MS, MN, and CM had full access to all the data in the study, RTL had fi nal responsibility for the decision to submit for publication, and all authors approved the decision to submit.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_yZ6gEH2">Results</head><p xml:id="_6fWveSu"><s xml:id="_FgYuNyr">Between May, 2007, and October, 2008, we enrolled 581 participants (fi gure 1).</s><s xml:id="_qfwnkeK">Consecutive enrolment was attempted; however, one site enrolled alternate patients into separate studies.</s><s xml:id="_5H4nrh6">After screening, 39 patients were excluded because they had inadequate phone access and four declined participation.</s><s xml:id="_FXZtES5">Accordingly, 538 patients were randomly assigned: 273 to the SMS intervention and 265 to standard care.</s><s xml:id="_2YeKcWm">Ten participants (seven in the SMS group and three in the control group) withdrew from the study after random allocation for personal reasons.</s><s xml:id="_JmXUktp">Table <ref type="table">1</ref> reports the demographics and baseline characteristics of both groups, which are generally similar to those of the AIDS epidemic in Kenya, including predominant female sex. <ref type="bibr" target="#b24">24</ref></s><s xml:id="_qdMrN6v">ore patients in the SMS intervention group than in the control group had self-reported adherence of over 95% at both visits (table 2).</s><s xml:id="_bqvN8Wv">By contrast, in the completecase analysis, adherence was not diff erent between groups.</s><s xml:id="_U8Kqmbu">After adjusting for baseline covariates, selfreported adherence remained signifi cantly better in the SMS group than the control group (odds ratio [OR] 0•57, 95% CI 0•40-0•83; p=0•0028).</s><s xml:id="_ZTbA3Jm">The NNT for adherence was nine (95% CI 5•0-29•5).</s></p><p xml:id="_bHGrVaD"><s xml:id="_UChzxAZ">More patients in the SMS group than in the control group had suppressed viral loads below the level of detection (&lt;400 copies per mL) at 12 months (table 2).</s><s xml:id="_SC9mvUm">In the complete-case analysis there was also higher viral suppression in the SMS group than the control group.</s><s xml:id="_3sNxQmA">After adjustment, the intention-to-treat analysis showed weak evidence of improved suppression of viral load in the SMS group compared with the control group (OR 0•71, 95% CI 0•50-1•01; p=0•058).</s><s xml:id="_Mhh9RFu">The NNT to achieve HIV-1 viral suppression was 11 (95% CI 5•8-227•3).</s></p><p xml:id="_EvNZsm9"><s xml:id="_uTNU2QX">No secondary outcomes showed signifi cant associations with the intervention (table 2). Figure <ref type="figure">2</ref> shows the results of the subgroup analysis and the heterogeneity of the intervention eff ect.</s><s xml:id="_k73cmG9">Male sex, urban</s></p><p xml:id="_9ExhTMv"><s xml:id="_yUCUZKm">SMS group (number [%]) Control group (number [%]) RR (95% CI)* p value Primary outcome Intention-to-treat analysis † Self-reported adherence (&gt;95%) 168 (62%) 132 (50%) 0•81 (0•69-0•94) 0•006 Viral suppression (&lt;400 copies per mL) 156 (57%) 128 (48%) 0•85 (0•72-0•99) 0•04 Complete-case analysis ‡ Self-reported adherence § 168 (91%) 132 (91%) 1•00 (0•94-1•07) 0•94 Viral suppression ¶ 156 (75%) 128 (66%) 0•88 (0•77-1•00) 0•047 Secondary outcomes Total attrition (missing) 53 (19%) 61 (23%) 1•24 (0•82-1•89) 0•31 Loss to follow-up 17 (6%) 27 (10%) 1•69 (0•91-3•23) 0•094 Mortality 25 (9%) 30 (11%) 1•27 (0•72-2•22) 0•42 Withdrawal 7 (3%) 3 (1%) 2•26 (0•59-8•67) 0•34|| Transfer out 4 (1%) 1 (0%) 0•25 (0•19-2•17) 0•38|| Percentages do not add up to 100% in some cases because of rounding.</s><s xml:id="_Qd9Qk4w">*For non-adherence or virologic failure.</s><s xml:id="_JPXkSkS">†273 patients in the SMS group and 265 in the control group.</s><s xml:id="_m7zaFZq">‡Because the intention-to-treat analysis classed all patients with missing data as non-adherent or having viral failure, the number of adherent patients and number of patients with viral suppression are the same here as in the intention-to-treat analysis.</s><s xml:id="_TaYTgNJ">§185 patients in the SMS group and 145 patients in the control group.</s><s xml:id="_UPXFbNx">¶208 patients in the SMS group and 194 patients in the control group.</s><s xml:id="_E9YqQ9Q">||Fisher's exact test.</s></p><p xml:id="_zFUuC2D"><s xml:id="_dCqwx2f">Table 2: Primary and secondary outcomes</s></p><p xml:id="_zd7RzV6"><s xml:id="_sX6wEn4">residence, and mobile phone ownership all favoured adherence compared with the control group.</s><s xml:id="_gVQVC8q">However, none was signifi cant after Bonferroni correction.</s><s xml:id="_QJYzcZN">We recorded 11 983 valid responses to the SMS inquiries from intervention participants.</s><s xml:id="_YAd94du">Figure <ref type="figure">3</ref> reports the patient responses over time.</s><s xml:id="_uHkSajV">There were 7812 "Sawa" responses, 391 "Shida" responses, and there were no responses or responses were not received on time on 3780 occasions.</s><s xml:id="_Z73WjdD">The proportion of Shida responses decreased from 6•1% in the fi rst 3 months after recruitment to 2•0% afterwards (p&lt;0•0001).</s><s xml:id="_4tMWrUz">The most common reason for a Shida response was a medical issue.</s><s xml:id="_83cwqZP">Non-responders most frequently cited cost and other logistical factors or forgetting, rather than health issues, as the main reasons for not responding on time.</s></p><p xml:id="_VHQE7wz"><s xml:id="_u8pAaV8">No adverse event directly attributable to the mobile phone SMS communication, such as breaches of confi dentiality (eg, if non-participants found out the participant's HIV status in an unintentional way) or injury (eg, caused by driving or riding a bike whilst texting), was reported in the weekly study logs or during follow-up visits with health-care workers.</s><s xml:id="_zgg8BdY">At the end of the study, 191 of 194 patients in the intervention group reported they would like the SMS programme to continue, of whom 188 (98%) said they would recommend it to a friend.</s><s xml:id="_bm7sTa8">In the focus group sessions, many patients in the intervention group also reported that they thought the SMS support service was valuable (data not shown).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_BaXfxqM">Discussion</head><p xml:id="_FDjcQSC"><s xml:id="_DYXFhkv">This study shows that mobile health innovations can improve HIV treatment outcomes.</s><s xml:id="_prmpsD8">Patients who received the SMS support were more likely to report adherence to ART and were more likely to have their viral load suppressed below detection levels than patients who received the standard care alone.</s></p><p xml:id="_tu48Wft"><s xml:id="_jXH5GRF">The primary analysis classed all-cause attrition as treatment failures.</s><s xml:id="_M2V9gak">Thus, the higher follow-up rates and</s></p><p xml:id="_juBjTRn"><s xml:id="_UzCCPDd">Sex Women Men Mobile phone Shares Owns Clinic Pumwani Kajiado Coptic WHO stage 1 2 3 4 Residence Rural Urban Overall 112/177 (63%) 56/96 (58%) 19/34 (56%) 149/239 (62%) 82/120 (68%) 16/36 (44%) 70/117 (60%) 36/52 (69%) 45/67 (67%) 54/101 (53%) 7/9 (78%) 29/51 (57%) 139/222 (63%) 168/273 (62%) 0 1 2 3 4 5 6 7 8 9 10 11 12 0 0•1 0•2 0•3 0•4 0•5 0•6 0•7 0•8 Proportion of weekly SMS responses Months Sawa (fine) No response Shida (problem) Figure 3: SMS intervention response rates The graph is truncated at 12 months' follow-up.</s><s xml:id="_PnmeStY">A line is drawn at 3 months indicating the usual transition to HIV disease stability and reduction in toxicities after initiation of antiretroviral therapy.</s></p><formula xml:id="formula_0">0•70 (0•46-1•07) 0•49 (0•27-0•88) 0•53 (0•21-1•33) 0•64 (0•44-0•93) 0•64 (0•38-1•08) 0•56 (0•22-1•42) 0•59 (0•34-1•02) 0•70 (0•32-1•53) 0•54 (0•26-1•11) 0•62 (0•36-1•08) 0•24 (0•04-1•66) 0•51 (0•23-1•12) 0•65 (0•44-0•95) 0•62 (0•44-0•88) 0•66 (0•43-1•00) 0•80 (0•45-1•42) 0•36 (0•14-0•94) 0•78 (0•54-1•12) 0•54 (0•33-0•89) 0•54 (0•22-1•34) 1•05 (0•61-1•81) 0•94 (0•44-1•98) 0•58 (0•28-1•17) 0•58 (0•33-1•00) 1•28 (0•23-7•19) 0•51 (0•23-1•12) 0•75 (0•52-1•10) 0•</formula><p xml:id="_jXjVSWZ"><s xml:id="_QJFMm6y">lower mortality reported in the intervention group contributed to the positive intervention eff ect for the primary outcomes.</s><s xml:id="_bCmSJDu">When only available data were included in the complete-case analyses, a signifi cant reduction was preserved in viral suppression but not in self-reported adherence.</s><s xml:id="_Yt3K23T">This could be because of a recall or social desirability bias in self-reporting adherence among those who were followed up.</s><s xml:id="_vzbKq7D">Alternatively, patients might have been less likely to respond to follow-up if they had not adhered to ART.</s><s xml:id="_GwUXcNw">Nonetheless, we chose an intention-totreat analysis for the primary outcome because contributions of loss to follow-up are important indicators for the durable implementation of ART programmes. <ref type="bibr" target="#b25">[25]</ref><ref type="bibr" target="#b26">[26]</ref></s><s xml:id="_vFSraVr">]<ref type="bibr" target="#b27">[27]</ref> Our reported adherence and viral suppression rates seem to be lower than in other studies; <ref type="bibr" target="#b28">28,</ref><ref type="bibr" target="#b29">29</ref> however, our detection of adherence failures might have been more sensitive because we used two timepoints for adherence, and comparative data on viral suppression outside of heavily researched settings is limited. <ref type="bibr" target="#b30">30</ref></s><s xml:id="_kSVxjRh">However, the actual mean adherence rates reported by participants in this study was quite high, and because the SMS intervention was well received by patients and the study consent process informed participants of potential benefi ts of mobile phone communication, the study might have underestimated the actual intervention eff ect compared with the regional standard care.</s><s xml:id="_t6C5spb">More mobile phone usage might have been promoted by the study overall; study nurses reported a higher number of calls from study control individuals compared with non-study clinic attendees (data not shown).</s><s xml:id="_8H4v4dZ">Additionally, several participants reported forwarding their weekly text messages to non-intervention participants to share support.</s><s xml:id="_FNwZg2e">Adherence rates reported among participants in this study were higher than non-study participants within the same clinics as well as non-study clinics operated by the same ART programme providers (ART adherence data provided by individual programme managers; data not shown).</s><s xml:id="_Q8cay84">The SMS intervention was well received by patients, many of whom reported that they felt "like someone cares"; most recommended for the SMS programme to continue (data not shown).</s><s xml:id="_QPgePWe">This is, to our knowledge, the fi rst eff ectiveness trial assessing the ability of a mobile health technology intervention to infl uence HIV outcomes in a resourcelimited setting (panel).</s><s xml:id="_47zZs6W">However, pilot studies of mobile health technologies are emerging. <ref type="bibr" target="#b31">[31]</ref><ref type="bibr" target="#b32">[32]</ref></s><s xml:id="_b8yYDzh">2]<ref type="bibr" target="#b33">[33]</ref><ref type="bibr" target="#b34">[34]</ref> In developed countries, mobile health technology interventions are gaining a clear evidence base for management and prevention of a broad range of disorders. <ref type="bibr" target="#b2">3,</ref><ref type="bibr" target="#b35">35</ref></s><s xml:id="_jgpRDh2">Two randomised trials in the USA assessed a counselling intervention by landline telephone for patients taking ART and reported a signifi cant benefi t for adherence but not for virologic control. <ref type="bibr" target="#b36">36,</ref><ref type="bibr" target="#b37">37</ref></s><s xml:id="_WPqx6ER">However, in our study the intervention included regular SMS communications without additional counselling, so human resource and training requirements were minimal.</s><s xml:id="_vz7FRum">Because only 3•3% of the weekly text messages identifi ed a defi nitive requirement for follow-up (Shida), one nurse could potentially manage 1000 patients by SMS and expect to call only 33 patients per week.</s><s xml:id="_49tS9xD">Additionally, the patient follow-up seemed to become more effi cient over time, because the proportion of Shida responses from patients decreased after the fi rst 3 months on ART; however, this decrease was after the period in which the most disease instability would be expected. <ref type="bibr" target="#b38">38</ref></s><s xml:id="_jhmtsD2">lthough some features of health care and communications are universal, developing and developed economic settings can have diff erent challenges and opportunities.</s><s xml:id="_kddUxGZ">Developing countries have resource challenges but might benefi t from bypassing less advanced technologies and instead using the most advanced methods available, which are more uniformly taken up and that allow fresh innovation.</s><s xml:id="_unaHGmM">Kenya, for instance, led the world in mobile phone money transfers, allowing people who never previously accessed banks to safely transfer funds routinely. <ref type="bibr" target="#b39">39</ref></s><s xml:id="_qbn6phJ">Mobile phones could also be used to support and track patients who transfer between ART provision sites.</s><s xml:id="_sU6uXD7">The political turmoil in Kenya after the 2007 presidential elections when hundreds of thousands of civilians were internally displaced because of ethnic violence <ref type="bibr" target="#b40">40</ref> occurred during our study period.</s><s xml:id="_yzNEazc">Although some mobile phones were lost, others were used to request assistance from clinic staff , which was frequently met with counselling support and directions to new, safe locales where drug refi lls could be obtained.</s><s xml:id="_VrgKxyz">Thus, the SMS service seemed to be durable in a crisis. <ref type="bibr" target="#b41">41</ref></s><s xml:id="_vMXf9Zj">verall, this study has implications for policy makers and global funders of ART programmes.</s><s xml:id="_VtQ45JM">First, this is one of the fi rst adherence interventions to confer a reduction in virologic failures. <ref type="bibr" target="#b42">42</ref></s><s xml:id="_JS3ExVB">ART needs to be taken lifelong, thus optimal adherence is crucial to the prevention of antiretroviral drug resistance.</s><s xml:id="_wphp6mT">Instances of drug resistance make future treatment options more challenging and progressively more expensive to deliver.</s><s xml:id="_u8BZn3N">Additionally, reducing viral replication through ART can decrease transmission of HIV-1 to new partners <ref type="bibr" target="#b43">43</ref> and thus can play a preventive role at the population level to reduce the number of new infections. <ref type="bibr" target="#b44">44,</ref><ref type="bibr" target="#b45">45</ref></s><s xml:id="_taux9Vk">nel: Research in context</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_VBMVDtf">Systematic review</head><p xml:id="_E3CdnTe"><s xml:id="_5hTgxQd">We searched Medline, Cochrane CENTRAL, and Embase (from inception to Oct 24, 2010) using the MeSH terms "cellular phone and HIV".</s><s xml:id="_hbF7Tuf">We did not identify any randomised controlled trials that have assessed mobile technology for treatment support in HIV patients.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_k4UueQ6">Interpretation</head><p xml:id="_HMFPJad"><s xml:id="_KNdM45d">This is, to our knowledge, the fi rst randomised controlled trial of mobile technology to support adherence and viral suppression in patients with HIV/AIDS.</s><s xml:id="_kFuBZkh">We reported a statistically signifi cant and clinically important increase in self-reported adherence and viral suppression.</s></p><p xml:id="_BajmeQj"><s xml:id="_XA58WTV">The SMS intervention is inexpensive (each SMS costs about US$0•05, equivalent to $20 per 100 patients per month, and follow-up voice calls averaged $3•75 per nurse per month) and the mobile phone protocol uses existing infrastructure.</s><s xml:id="_kbUrVUX">This protocol is also probably less expensive than in-person community adherence interventions, <ref type="bibr" target="#b30">30,</ref><ref type="bibr" target="#b46">46,</ref><ref type="bibr" target="#b47">47</ref> on the basis of travel costs alone.</s><s xml:id="_sJxtTM9">Thus, the intervention could be both cost eff ective and cost saving.</s><s xml:id="_4kM9FYB">The estimated NNT of 11 patients for each additional patient with viral suppression in the SMS group over the standard care group could theoretically translate into huge health and economic benefi ts if the programme was successfully scaled up.</s><s xml:id="_GmVAa7R">For example, if hypothetically applied to the 297 800 people who received ART in Kenya's PEPFAR programme in 2009 (and assuming the eff ect went beyond 1 year), the SMS intervention could have resulted in 26 354 additional people with fully suppressed viral loads.</s><s xml:id="_rAe9rff">Innovations in management of automated text messaging and public-private partnerships with mobile health technology developers could improve programme effi ciency and scalability.</s></p><p xml:id="_RaW2wdA"><s xml:id="_tGdxTTr">The applicability of this study to other countries and other diseases remains to be assessed.</s><s xml:id="_mngRRAe">Factors that infl uence adherence are often common within Africa and other global settings. <ref type="bibr" target="#b48">48,</ref><ref type="bibr" target="#b49">49</ref></s><s xml:id="_dqFGXcA">Although the uptake of wireless telecommunication devices is becoming ubiquitous, introduction of mobile health initiatives is variable. <ref type="bibr" target="#b0">1,</ref><ref type="bibr" target="#b50">50</ref></s><s xml:id="_WJDjcQU">We believe that the patient-centred communication eff ect, in particular the timely support of a patient by a health professional, is universal and can be improved by mobile telecommunication.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_a8RACKv">Contributors</head><p xml:id="_vFr7mB5"><s xml:id="_XPWEDDa">RTL conceived the study and was the principal investigator of the funded public health evaluation.</s><s xml:id="_sHSbT9y">PR, AK, SK, MHC, WJ, JH, and EN designed the study and BE, LJG, and JK helped with implementation.</s><s xml:id="_sn7vTQc">RTL, MHC, LJG, JK, and FAP are holders of grants that broadly support the ART clinics and research programmes.</s><s xml:id="_wuxkqbG">EJM and LT provided statistical expertise in clinical trial design.</s><s xml:id="_eEDWJkC">MS and MN, supervised by CAM, did the primary statistical analysis.</s><s xml:id="_GRHjUeC">All authors contributed to refi nement of the study protocol and approved the fi nal manuscript.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_C2aXQXP">Confl icts of interest</head><p xml:id="_FRwcEn8"><s xml:id="_B8eNdKV">MA is an employee of the US Centers for Disease Control and Prevention (CDC).</s><s xml:id="_UAtVZ68">All other authors declare that they have no confl ict of interest.</s></p></div><figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_0"><head>Figure 1 :</head><label>1</label><figDesc><div><p xml:id="_fhex7mh"><s xml:id="_WwnuvUM">Figure 1: Trial profi le</s></p></div></figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_1"><head>Figure 2 :Figure 3 :</head><label>23</label><figDesc><div><p xml:id="_UvdRyny"><s xml:id="_RapZUDK">Figure 2: Subgroup analyses Estimated intervention eff ects are reported as ORs and 95% CIs for risk of failure.</s><s xml:id="_WCkA3Gk">p values for heterogeneity were derived from likelihood ratio statistics.</s><s xml:id="_F6vhhtZ">OR=odds ratio.</s></p></div></figDesc></figure>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot" xml:id="foot_0"><p xml:id="_EtJGesU"><s xml:id="_schpmWK">www.thelancet.com</s><s xml:id="_5gDVzk5">Vol 376 November 27, 2010</s></p></note>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot" xml:id="foot_1"><p xml:id="_2CwYpTN"><s xml:id="_KWYcct6">www.thelancet.com</s><s xml:id="_AkKskDx">Vol 376 November 27, 2010</s></p></note>
		</body>
		<back>

			<div type="acknowledgement">
<div><head xml:id="_jkTeq3P">Acknowledgments</head><p xml:id="_BRkycRW"><s xml:id="_eHJ3GmT">The trial was funded by the <rs type="funder">US President's Emergency Plan for AIDS Relief (PEPFAR)</rs> through the <rs type="funder">CDC</rs> cooperative agreement <rs type="grantNumber">5U62PS024510</rs> as a public-health evaluation (PHE:<rs type="grantNumber">KE07.0045</rs>).</s><s xml:id="_ttqGwBU">The <rs type="funder">Coptic Hope Center for Infectious Diseases</rs> is supported by <rs type="funder">PEPFAR</rs> through the <rs type="funder">CDC cooperative agreement</rs> (<rs type="grantNumber">U62/CCU024512-04</rs>).</s><s xml:id="_jfMhaeW">Kajiado District Hospital Comprehensive Care Clinic is supported by the <rs type="funder">Government of Kenya Ministry of Health</rs> and <rs type="programName">APHIA II programme</rs>.</s><s xml:id="_8bgscZy">RTL was supported by an unrestricted research award through <rs type="funder">Association of Medical Microbiology and Infectious Diseases-Bristol-Myers-Squibb (Canada)</rs> and a <rs type="funder">Canadian Institute for Health Research (CIHR)</rs> training award, and from the <rs type="funder">University of Manitoba</rs> hosted <rs type="funder">CIHR/ICID (International Center for Infectious Diseases) National Training Program in Infectious Diseases</rs>.</s></p><p xml:id="_M6ayU2G"><s xml:id="_28WWGqe">EJM is a tier 2 Canada Research Chair in global health.</s><s xml:id="_YHvuQQ7">MHC was supported by a <rs type="grantName">K23 grant</rs> from the <rs type="funder">National Institutes of Health</rs> (<rs type="grantNumber">5K23AI065222-04</rs>).</s><s xml:id="_w6tNT78">FAP is a tier 1 Canada Research Chair in resistance and susceptibility to infections.</s><s xml:id="_znf7z5q">The fi ndings and conclusions in this paper are those of the authors and do not necessarily represent the offi cial position of the funding agencies.</s><s xml:id="_udBX4C4">We thank the health-care staff and patients who participated in the study.</s><s xml:id="_gJRzvV3">We dedicate our greatest thanks to our Kenyan statistician, <rs type="person">Rosemary Ngugi</rs>, who died of cancer during preparation of this manuscript.</s></p></div>
			</div>
			<listOrg type="funding">
				<org type="funding" xml:id="_xeTffuG">
					<idno type="grant-number">5U62PS024510</idno>
				</org>
				<org type="funding" xml:id="_wCDzPxu">
					<idno type="grant-number">KE07.0045</idno>
				</org>
				<org type="funding" xml:id="_JSuFB8g">
					<idno type="grant-number">U62/CCU024512-04</idno>
				</org>
				<org type="funding" xml:id="_rV8NxR3">
					<orgName type="program" subtype="full">APHIA II programme</orgName>
				</org>
				<org type="funding" xml:id="_yNNhV8Y">
					<idno type="grant-number">5K23AI065222-04</idno>
					<orgName type="grant-name">K23 grant</orgName>
				</org>
			</listOrg>
			<div type="references">

				<listBibl>

<biblStruct xml:id="b0">
	<analytic>
		<title level="a" type="main" xml:id="_9nCruph">Can the ubiquitous power of mobile phones be used to improve health outcomes in developing countries?</title>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">A</forename><surname>Kaplan</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_qP9tZFD">Global Health</title>
		<imprint>
			<biblScope unit="volume">2</biblScope>
			<biblScope unit="issue">9</biblScope>
			<date type="published" when="2006">2006</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Kaplan WA. Can the ubiquitous power of mobile phones be used to improve health outcomes in developing countries? Global Health 2006; 2: 9.</note>
</biblStruct>

<biblStruct xml:id="b1">
	<analytic>
		<title level="a" type="main" xml:id="_RPCmEVq">Developing solutions</title>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">V</forename><surname>Padma</surname></persName>
		</author>
		<idno type="DOI">10.1038/nature09242</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_KxfRRPD">Nature</title>
		<imprint>
			<biblScope unit="volume">466</biblScope>
			<biblScope unit="page" from="16" to="17" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
	<note>2</note>
	<note type="raw_reference">2 Padma TV. Developing solutions. Nature 2010; 466: S16-17.</note>
</biblStruct>

<biblStruct xml:id="b2">
	<analytic>
		<title level="a" type="main" xml:id="_B5Vtqp2">Healthcare via cell phones: a systematic review</title>
		<author>
			<persName><forename type="first">S</forename><surname>Krishna</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">A</forename><surname>Boren</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">A</forename><surname>Balas</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_2aCMSqV">Telemed J E Health</title>
		<imprint>
			<biblScope unit="volume">15</biblScope>
			<biblScope unit="page" from="231" to="240" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Krishna S, Boren SA, Balas EA. Healthcare via cell phones: a systematic review. Telemed J E Health 2009; 15: 231-40.</note>
</biblStruct>

<biblStruct xml:id="b3">
	<analytic>
		<title level="a" type="main" xml:id="_RGFa9sh">The global fi ght against HIV/AIDS, tuberculosis, and malaria: current status and future perspectives</title>
		<author>
			<persName><forename type="first">M</forename><surname>Vitoria</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Granich</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">F</forename><surname>Gilks</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_TbffM8n">Am J Clin Pathol</title>
		<imprint>
			<biblScope unit="volume">131</biblScope>
			<biblScope unit="page" from="844" to="848" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Vitoria M, Granich R, Gilks CF, et al. The global fi ght against HIV/AIDS, tuberculosis, and malaria: current status and future perspectives. Am J Clin Pathol 2009; 131: 844-48.</note>
</biblStruct>

<biblStruct xml:id="b4">
	<monogr>
		<title level="m" type="main" xml:id="_ugm22RZ">Telecom: tools connecting the world and communicating about HIV</title>
		<ptr target="http://www.unaids.org/en/KnowledgeCentre/Resources/FeatureStories/archive/2009/20091005_telecom.asp" />
		<imprint>
			<date type="published" when="2009-10-05">2009 Oct 5. May 20, 2010</date>
			<publisher>UNAIDS</publisher>
		</imprint>
	</monogr>
	<note type="raw_reference">UNAIDS. Telecom: tools connecting the world and communicating about HIV. 2009 Oct 5. http://www.unaids.org/en/Knowledge Centre/Resources/FeatureStories/archive/2009/20091005_telecom. asp (accessed May 20, 2010).</note>
</biblStruct>

<biblStruct xml:id="b5">
	<analytic>
		<title level="a" type="main" xml:id="_VAZXpAp">Integrating HIV care and HIV prevention: legal, policy and programmatic recommendations</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">H</forename><surname>Remien</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Berkman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Myer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">I</forename><surname>Bastos</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Kagee</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">M</forename><surname>El-Sadr</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_hb7yRcv">AIDS</title>
		<imprint>
			<biblScope unit="volume">22</biblScope>
			<biblScope unit="issue">suppl 2</biblScope>
			<biblScope unit="page" from="57" to="65" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Remien RH, Berkman A, Myer L, Bastos FI, Kagee A, El-Sadr WM. Integrating HIV care and HIV prevention: legal, policy and programmatic recommendations. AIDS 2008; 22 (suppl 2): S57-65.</note>
</biblStruct>

<biblStruct xml:id="b6">
	<analytic>
		<title level="a" type="main" xml:id="_jx7XHrt">The spread, treatment, and prevention of HIV-1: evolution of a global pandemic</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">S</forename><surname>Cohen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Hellmann</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">A</forename><surname>Levy</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Decock</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Lange</surname></persName>
		</author>
		<idno type="DOI">10.1172/jci34706</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_Sby75wB">J Clin Invest</title>
		<imprint>
			<biblScope unit="volume">118</biblScope>
			<biblScope unit="page" from="1244" to="1254" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Cohen MS, Hellmann N, Levy JA, DeCock K, Lange J. The spread, treatment, and prevention of HIV-1: evolution of a global pandemic. J Clin Invest 2008; 118: 1244-54.</note>
</biblStruct>

<biblStruct xml:id="b7">
	<analytic>
		<title level="a" type="main" xml:id="_uaVCARx">Cellular-news</title>
		<idno type="DOI">10.1109/giis.2009.5307104</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_tAsruSE">Global Mobile Phone Subscribers to Reach</title>
		<imprint>
			<biblScope unit="volume">4</biblScope>
			<biblScope unit="issue">5</biblScope>
		</imprint>
	</monogr>
	<note type="raw_reference">Cellular-news. Global Mobile Phone Subscribers to Reach 4.5</note>
</biblStruct>

<biblStruct xml:id="b8">
	<monogr>
		<idno type="DOI">10.2307/jj.32047683.7</idno>
		<ptr target="http://www.cellular-news.com/story/29824.php" />
		<title level="m" xml:id="_eYaKmAq">Billion</title>
		<imprint>
			<date type="published" when="2010">2012. June 15, 2010</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Billion by 2012. http://www.cellular-news.com/story/29824.php (accessed June 15, 2010).</note>
</biblStruct>

<biblStruct xml:id="b9">
	<analytic>
		<title level="a" type="main" xml:id="_PU66hY3">Eff ect of medication adherence on survival of HIV-infected adults who start highly active antiretroviral therapy when the CD4+ cell count is 0•200 to 0•350 × 10(9) cells/L</title>
		<author>
			<persName><forename type="first">E</forename><surname>Wood</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">S</forename><surname>Hogg</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Yip</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">R</forename><surname>Harrigan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O'</forename><surname>Shaughnessy</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">V</forename><surname>Montaner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">S</forename></persName>
		</author>
		<idno type="DOI">10.7326/0003-4819-139-10-200311180-00008</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_ZVs48HG">Ann Intern Med</title>
		<imprint>
			<biblScope unit="volume">139</biblScope>
			<biblScope unit="page" from="810" to="816" />
			<date type="published" when="2003">2003</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Wood E, Hogg RS, Yip B, Harrigan PR, O&apos;Shaughnessy MV, Montaner JS. Eff ect of medication adherence on survival of HIV-infected adults who start highly active antiretroviral therapy when the CD4+ cell count is 0•200 to 0•350 × 10(9) cells/L. Ann Intern Med 2003; 139: 810-16.</note>
</biblStruct>

<biblStruct xml:id="b10">
	<analytic>
		<title level="a" type="main" xml:id="_9CSpy7t">The World Health Organization&apos;s global strategy for prevention and assessment of HIV drug resistance</title>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">E</forename><surname>Bennett</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Bertagnolio</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Sutherland</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">F</forename><surname>Gilks</surname></persName>
		</author>
		<idno type="DOI">10.1177/135965350801302s03</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_gD3qawh">Antivir Ther</title>
		<imprint>
			<biblScope unit="volume">13</biblScope>
			<biblScope unit="issue">suppl 2</biblScope>
			<biblScope unit="page" from="1" to="13" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Bennett DE, Bertagnolio S, Sutherland D, Gilks CF. The World Health Organization&apos;s global strategy for prevention and assessment of HIV drug resistance. Antivir Ther 2008; 13 (suppl 2): 1-13.</note>
</biblStruct>

<biblStruct xml:id="b11">
	<analytic>
		<title level="a" type="main" xml:id="_gNdjfTu">The impact of HIV scale-up on health systems: a priority research agenda</title>
		<author>
			<persName><forename type="first">M</forename><surname>Rabkin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">M</forename><surname>El-Sadr</surname></persName>
		</author>
		<author>
			<persName><forename type="first">De</forename><surname>Cock</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">M</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_stvQ2SP">J Acquir Immune Defi c Syndr</title>
		<imprint>
			<biblScope unit="volume">52</biblScope>
			<biblScope unit="issue">suppl 1</biblScope>
			<biblScope unit="page" from="6" to="11" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Rabkin M, El-Sadr WM, De Cock KM. The impact of HIV scale-up on health systems: a priority research agenda. J Acquir Immune Defi c Syndr 2009; 52 (suppl 1): S6-11.</note>
</biblStruct>

<biblStruct xml:id="b12">
	<analytic>
		<title level="a" type="main" xml:id="_VxQBaEb">Mobilizing cell phones to improve antiretroviral adherence and follow-up in Kenya: a randomized controlled trial in progress</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">T</forename><surname>Lester</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Kariri</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_5BjtTKD">WHO Essential Medicines Monitor</title>
		<imprint>
			<biblScope unit="volume">2</biblScope>
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
	<note>Article 1</note>
	<note type="raw_reference">Lester RT, Kariri A. Mobilizing cell phones to improve antiretroviral adherence and follow-up in Kenya: a randomized controlled trial in progress. WHO Essential Medicines Monitor 2009; 2: Article 1.</note>
</biblStruct>

<biblStruct xml:id="b13">
	<analytic>
		<title level="a" type="main" xml:id="_zVSwF8n">AIDS virus infection in Nairobi prostitutes. Spread of the epidemic to East Africa</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">K</forename><surname>Kreiss</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Koech</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">A</forename><surname>Plummer</surname></persName>
		</author>
		<idno type="DOI">10.1056/nejm198602133140704</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_5YR3RrG">N Engl J Med</title>
		<imprint>
			<biblScope unit="volume">314</biblScope>
			<biblScope unit="page" from="414" to="418" />
			<date type="published" when="1986">1986</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Kreiss JK, Koech D, Plummer FA, et al. AIDS virus infection in Nairobi prostitutes. Spread of the epidemic to East Africa. N Engl J Med 1986; 314: 414-18.</note>
</biblStruct>

<biblStruct xml:id="b14">
	<analytic>
		<title level="a" type="main" xml:id="_pBFY9cb">Impact of prior HAART use on clinical outcomes in a large Kenyan HIV treatment program</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">H</forename><surname>Chung</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">L</forename><surname>Drake</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">A</forename><surname>Richardson</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_aZ4fbjk">Curr HIV Res</title>
		<imprint>
			<biblScope unit="volume">7</biblScope>
			<biblScope unit="page" from="441" to="446" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Chung MH, Drake AL, Richardson BA, et al. Impact of prior HAART use on clinical outcomes in a large Kenyan HIV treatment program. Curr HIV Res 2009; 7: 441-46.</note>
</biblStruct>

<biblStruct xml:id="b15">
	<analytic>
		<title level="a" type="main" xml:id="_RjennSp">Unequal group sizes in randomised trials: guarding against guessing</title>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">F</forename><surname>Schulz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">A</forename><surname>Grimes</surname></persName>
		</author>
		<idno type="DOI">10.1016/s0140-6736(02)08029-7</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_EDuQRsn">Lancet</title>
		<imprint>
			<biblScope unit="volume">359</biblScope>
			<biblScope unit="page" from="966" to="970" />
			<date type="published" when="2002">2002</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Schulz KF, Grimes DA. Unequal group sizes in randomised trials: guarding against guessing. Lancet 2002; 359: 966-70.</note>
</biblStruct>

<biblStruct xml:id="b16">
	<analytic>
		<title level="a" type="main" xml:id="_TMkrU4P">Guidelines for antiretroviral drug therapy in Kenya, 3rd edn</title>
		<idno type="DOI">10.1097/qad.0b013e3280117fa5</idno>
		<ptr target="http://www.aidskenya.org/public_site/webroot/cache/article/file/ART_GUIDELINES.pdf" />
	</analytic>
	<monogr>
		<title level="m" xml:id="_ykwcYNP">National AIDS and STI Control Programme (NASCOP) MoH</title>
		<imprint>
			<date type="published" when="2005-06-15">2005. June 15, 2010</date>
		</imprint>
	</monogr>
	<note type="raw_reference">National AIDS and STI Control Programme (NASCOP) MoH. Guidelines for antiretroviral drug therapy in Kenya, 3rd edn. 2005. http://www.aidskenya.org/public_site/webroot/cache/article/fi le/ ART_GUIDELINES.pdf (accessed June 15, 2010).</note>
</biblStruct>

<biblStruct xml:id="b17">
	<analytic>
		<title level="a" type="main" xml:id="_uepuGH7">Cell phones: tightening the communication gap in resource-limited antiretroviral programmes?</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">T</forename><surname>Lester</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Gelmon</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">A</forename><surname>Plummer</surname></persName>
		</author>
		<idno type="DOI">10.1097/qad.0b013e3280108508</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_ksRsdjv">AIDS</title>
		<imprint>
			<biblScope unit="volume">20</biblScope>
			<biblScope unit="page" from="2242" to="2244" />
			<date type="published" when="2006">2006</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Lester RT, Gelmon L, Plummer FA. Cell phones: tightening the communication gap in resource-limited antiretroviral programmes? AIDS 2006; 20: 2242-44.</note>
</biblStruct>

<biblStruct xml:id="b18">
	<analytic>
		<title level="a" type="main" xml:id="_n63tssH">Multiple validated measures of adherence indicate high levels of adherence to generic HIV antiretroviral therapy in a resource-limited setting</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">H</forename><surname>Oyugi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Byakika-Tusiime</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">D</forename><surname>Charlebois</surname></persName>
		</author>
		<idno type="DOI">10.1097/00126334-200408150-00014</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_sCBuzpX">J Acquir Immune Defi c Syndr</title>
		<imprint>
			<biblScope unit="volume">36</biblScope>
			<biblScope unit="page" from="1100" to="1102" />
			<date type="published" when="2004">2004</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Oyugi JH, Byakika-Tusiime J, Charlebois ED, et al. Multiple validated measures of adherence indicate high levels of adherence to generic HIV antiretroviral therapy in a resource-limited setting. J Acquir Immune Defi c Syndr 2004; 36: 1100-02.</note>
</biblStruct>

<biblStruct xml:id="b19">
	<analytic>
		<title level="a" type="main" xml:id="_EqPT4e6">Self-report measures of antiretroviral therapy adherence: a review with recommendations for HIV research and clinical management</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">M</forename><surname>Simoni</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">E</forename><surname>Kurth</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">R</forename><surname>Pearson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">W</forename><surname>Pantalone</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">O</forename><surname>Merrill</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">A</forename><surname>Frick</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_TrsDYBR">AIDS Behav</title>
		<imprint>
			<biblScope unit="volume">10</biblScope>
			<biblScope unit="page" from="227" to="245" />
			<date type="published" when="2006">2006</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Simoni JM, Kurth AE, Pearson CR, Pantalone DW, Merrill JO, Frick PA. Self-report measures of antiretroviral therapy adherence: a review with recommendations for HIV research and clinical management. AIDS Behav 2006; 10: 227-45.</note>
</biblStruct>

<biblStruct xml:id="b20">
	<analytic>
		<title level="a" type="main" xml:id="_gQMjUYf">The HAART cell phone adherence trial (WelTel Kenya1): a randomized controlled trial protocol</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">T</forename><surname>Lester</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">J</forename><surname>Mills</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Kariri</surname></persName>
		</author>
		<idno type="DOI">10.1186/1745-6215-10-87</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_d8wc9Ty">Trials</title>
		<imprint>
			<biblScope unit="volume">10</biblScope>
			<biblScope unit="page">87</biblScope>
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Lester RT, Mills EJ, Kariri A, et al. The HAART cell phone adherence trial (WelTel Kenya1): a randomized controlled trial protocol. Trials 2009; 10: 87.</note>
</biblStruct>

<biblStruct xml:id="b21">
	<analytic>
		<title level="a" type="main" xml:id="_NTnMbaE">Viability and eff ectiveness of large-scale HIV treatment initiatives in sub-Saharan Africa: experience from western Kenya</title>
		<author>
			<persName><forename type="first">K</forename><surname>Wools-Kaloustian</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Kimaiyo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Diero</surname></persName>
		</author>
		<idno type="DOI">10.1097/01.aids.0000196177.65551.ea</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_FGvUdY4">AIDS</title>
		<imprint>
			<biblScope unit="volume">20</biblScope>
			<biblScope unit="page" from="41" to="48" />
			<date type="published" when="2006">2006</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Wools-Kaloustian K, Kimaiyo S, Diero L, et al. Viability and eff ectiveness of large-scale HIV treatment initiatives in sub-Saharan Africa: experience from western Kenya. AIDS 2006; 20: 41-48.</note>
</biblStruct>

<biblStruct xml:id="b22">
	<analytic>
		<title level="a" type="main" xml:id="_YUNVFtQ">Adjusting for multiple testing in studies is less important than other concerns</title>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">V</forename><surname>Perneger</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_KecneJ5">BMJ</title>
		<imprint>
			<biblScope unit="volume">318</biblScope>
			<biblScope unit="page">1288</biblScope>
			<date type="published" when="1999">1999</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Perneger TV. Adjusting for multiple testing in studies is less important than other concerns. BMJ 1999; 318: 1288.</note>
</biblStruct>

<biblStruct xml:id="b23">
	<analytic>
		<title level="a" type="main" xml:id="_v6WfYhk">Confi dence intervals for the number needed to treat</title>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">G</forename><surname>Altman</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_d5XDNf3">BMJ</title>
		<imprint>
			<biblScope unit="volume">317</biblScope>
			<biblScope unit="page" from="1309" to="1312" />
			<date type="published" when="1998">1998</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Altman DG. Confi dence intervals for the number needed to treat. BMJ 1998; 317: 1309-12.</note>
</biblStruct>

<biblStruct xml:id="b24">
	<monogr>
		<idno type="DOI">10.31899/hiv12.1034</idno>
		<ptr target="http://www.aidsportal.org/repos/KAIS%20-%20Preliminary%20Report_July%20291.pdf" />
		<title level="m" xml:id="_8Ys9Fbq">Kenya AIDS indicator survey 2007</title>
		<meeting><address><addrLine>Nairobi, Kenya</addrLine></address></meeting>
		<imprint>
			<date type="published" when="2008-07">July 2008. June 15, 2010</date>
		</imprint>
		<respStmt>
			<orgName>National AIDS and STI Control Programme, Ministry of Health, Kenya</orgName>
		</respStmt>
	</monogr>
	<note>preliminary report</note>
	<note type="raw_reference">National AIDS and STI Control Programme, Ministry of Health, Kenya. July 2008. Kenya AIDS indicator survey 2007: preliminary report. Nairobi, Kenya. (http://www.aidsportal.org/repos/KAIS% 20-%20Preliminary%20Report_July%20291.pdf) (accessed June 15, 2010).</note>
</biblStruct>

<biblStruct xml:id="b25">
	<analytic>
		<title level="a" type="main" xml:id="_bbancHp">Patient retention in antiretroviral therapy programs in sub-Saharan Africa: a systematic review</title>
		<author>
			<persName><forename type="first">S</forename><surname>Rosen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">P</forename><surname>Fox</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">J</forename><surname>Gill</surname></persName>
		</author>
		<idno type="DOI">10.1371/journal.pmed.0040298</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_hxfCcUj">PLoS Med</title>
		<imprint>
			<biblScope unit="volume">4</biblScope>
			<biblScope unit="page">e298</biblScope>
			<date type="published" when="2007">2007</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Rosen S, Fox MP, Gill CJ. Patient retention in antiretroviral therapy programs in sub-Saharan Africa: a systematic review. PLoS Med 2007; 4: e298.</note>
</biblStruct>

<biblStruct xml:id="b26">
	<analytic>
		<title level="a" type="main" xml:id="_sXdEPtb">Mortality of patients lost to follow-up in antiretroviral treatment programmes in resource-limited settings: systematic review and meta-analysis</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">W</forename><surname>Brinkhof</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Pujades-Rodriguez</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Egger</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_XWJPem2">PLoS One</title>
		<imprint>
			<biblScope unit="volume">4</biblScope>
			<biblScope unit="page">5790</biblScope>
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Brinkhof MW, Pujades-Rodriguez M, Egger M. Mortality of patients lost to follow-up in antiretroviral treatment programmes in resource-limited settings: systematic review and meta-analysis. PLoS One 2009; 4: e5790.</note>
</biblStruct>

<biblStruct xml:id="b27">
	<analytic>
		<title level="a" type="main" xml:id="_Ep5r8JA">Cost-eff ectiveness of preventing loss to follow-up in HIV treatment programs: a Cote d&apos;Ivoire appraisal</title>
		<author>
			<persName><forename type="first">E</forename><surname>Losina</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Toure</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">M</forename><surname>Uhler</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_w3eFmCT">PLoS Med</title>
		<imprint>
			<biblScope unit="volume">6</biblScope>
			<biblScope unit="page">1000173</biblScope>
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Losina E, Toure H, Uhler LM, et al. Cost-eff ectiveness of preventing loss to follow-up in HIV treatment programs: a Cote d&apos;Ivoire appraisal. PLoS Med 2009; 6: e1000173.</note>
</biblStruct>

<biblStruct xml:id="b28">
	<analytic>
		<title level="a" type="main" xml:id="_k7zKkBR">Ascertaining baseline levels of antiretroviral therapy adherence in Uganda: a multimethod approach</title>
		<author>
			<persName><forename type="first">S</forename><surname>Kunutsor</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Evans</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Thoulass</surname></persName>
		</author>
		<idno type="DOI">10.1097/qai.0b013e3181e255ec</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_TyzsyZc">J Acquir Immune Defi c Syndr</title>
		<imprint>
			<biblScope unit="volume">55</biblScope>
			<biblScope unit="page" from="221" to="224" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Kunutsor S, Evans M, Thoulass J, et al. Ascertaining baseline levels of antiretroviral therapy adherence in Uganda: a multimethod approach. J Acquir Immune Defi c Syndr 2010; 55: 221-24.</note>
</biblStruct>

<biblStruct xml:id="b29">
	<analytic>
		<title level="a" type="main" xml:id="_uEyjwyP">Eff ectiveness of highly active antiretroviral therapy administered by general practitioners in rural South Africa</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">E</forename><surname>Barth</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">T</forename><surname>Van Der Meer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">I</forename><surname>Hoepelman</surname></persName>
		</author>
		<idno type="DOI">10.1007/s10096-008-0534-2</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_MnPQJYF">Eur J Clin Microbiol Infect Dis</title>
		<imprint>
			<biblScope unit="volume">27</biblScope>
			<biblScope unit="page" from="977" to="984" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Barth RE, van der Meer JT, Hoepelman AI, et al. Eff ectiveness of highly active antiretroviral therapy administered by general practitioners in rural South Africa. Eur J Clin Microbiol Infect Dis 2008; 27: 977-84.</note>
</biblStruct>

<biblStruct xml:id="b30">
	<analytic>
		<title level="a" type="main" xml:id="_tH3vSqD">Eff ect of peer health workers on AIDS care in Rakai, Uganda: a cluster-randomized trial</title>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">W</forename><surname>Chang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Kagaayi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Nakigozi</surname></persName>
		</author>
		<idno type="DOI">10.1371/journal.pone.0010923</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_Exnsju6">PLoS One</title>
		<imprint>
			<biblScope unit="volume">5</biblScope>
			<biblScope unit="page">e10923</biblScope>
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Chang LW, Kagaayi J, Nakigozi G, et al. Eff ect of peer health workers on AIDS care in Rakai, Uganda: a cluster-randomized trial. PLoS One 2010; 5: e10923.</note>
</biblStruct>

<biblStruct xml:id="b31">
	<analytic>
		<title level="a" type="main" xml:id="_vUxwgD4">Access, use and perceptions regarding Internet, cell phones and PDAs as a means for health promotion for people living with HIV in Peru</title>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">H</forename><surname>Curioso</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">E</forename><surname>Kurth</surname></persName>
		</author>
		<idno type="DOI">10.1186/1472-6947-7-24</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_tf5aHfM">BMC Med Inform Decis Mak</title>
		<imprint>
			<biblScope unit="volume">7</biblScope>
			<biblScope unit="page">24</biblScope>
			<date type="published" when="2007">2007</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Curioso WH, Kurth AE. Access, use and perceptions regarding Internet, cell phones and PDAs as a means for health promotion for people living with HIV in Peru. BMC Med Inform Decis Mak 2007; 7: 24.</note>
</biblStruct>

<biblStruct xml:id="b32">
	<analytic>
		<title level="a" type="main" xml:id="_eCpgk8a">Mobile direct observation treatment for tuberculosis patients: a technical feasibility pilot using mobile phones in Nairobi, Kenya</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">A</forename><surname>Hoff Man</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">R</forename><surname>Cunningham</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">J</forename><surname>Suleh</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.amepre.2010.02.018</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_fFVXYhU">Am J Prev Med</title>
		<imprint>
			<biblScope unit="volume">39</biblScope>
			<biblScope unit="page" from="78" to="80" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Hoff man JA, Cunningham JR, Suleh AJ, et al. Mobile direct observation treatment for tuberculosis patients: a technical feasibility pilot using mobile phones in Nairobi, Kenya. Am J Prev Med 2010; 39: 78-80.</note>
</biblStruct>

<biblStruct xml:id="b33">
	<analytic>
		<title level="a" type="main" xml:id="_GCEcBPW">Challenges in using mobile phones for collection of antiretroviral therapy adherence data in a resource-limited setting</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">E</forename><surname>Haberer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Kiwanuka</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Nansera</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><forename type="middle">B</forename><surname>Wilson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">R</forename><surname>Bangsberg</surname></persName>
		</author>
		<idno type="DOI">10.1007/s10461-010-9720-1</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_HsPnMwM">AIDS Behav</title>
		<imprint>
			<date type="published" when="2010-06-08">2010. June 8</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Haberer JE, Kiwanuka J, Nansera D, Wilson IB, Bangsberg DR. Challenges in using mobile phones for collection of antiretroviral therapy adherence data in a resource-limited setting. AIDS Behav 2010; published online June 8. DOI:10.1007/s10461-010-9720-1.</note>
</biblStruct>

<biblStruct xml:id="b34">
	<analytic>
		<title level="a" type="main" xml:id="_cTyeWNY">Cell phone short messaging service (SMS) for HIV/AIDS in South Africa: a literature review</title>
		<author>
			<persName><forename type="first">Mukund</forename><surname>Bahadur</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">C</forename><surname>Murray</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">J</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_BBFR9mm">Stud Health Technol Inform</title>
		<imprint>
			<biblScope unit="volume">160</biblScope>
			<biblScope unit="page" from="530" to="534" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Mukund Bahadur KC, Murray PJ. Cell phone short messaging service (SMS) for HIV/AIDS in South Africa: a literature review. Stud Health Technol Inform 2010; 160: 530-34.</note>
</biblStruct>

<biblStruct xml:id="b35">
	<analytic>
		<title level="a" type="main" xml:id="_n9AGQCt">A daily SMS reminder increases adherence to asthma treatment: a three-month follow-up study</title>
		<author>
			<persName><forename type="first">U</forename><surname>Strandbygaard</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">F</forename><surname>Thomsen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Backer</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.rmed.2009.10.003</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_ZsZwH9D">Respir Med</title>
		<imprint>
			<biblScope unit="volume">104</biblScope>
			<biblScope unit="page" from="166" to="171" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Strandbygaard U, Thomsen SF, Backer V. A daily SMS reminder increases adherence to asthma treatment: a three-month follow-up study. Respir Med 2010; 104: 166-71.</note>
</biblStruct>

<biblStruct xml:id="b36">
	<analytic>
		<title level="a" type="main" xml:id="_kTAQe7Z">A randomized study of serial telephone call support to increase adherence and thereby improve virologic outcome in persons initiating antiretroviral therapy</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">C</forename><surname>Collier</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Ribaudo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">L</forename><surname>Mukherjee</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Feinberg</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">A</forename><surname>Fischl</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Chesney</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_XVyrARf">J Infect Dis</title>
		<imprint>
			<biblScope unit="volume">192</biblScope>
			<biblScope unit="page" from="1398" to="1406" />
			<date type="published" when="2005">2005</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Collier AC, Ribaudo H, Mukherjee AL, Feinberg J, Fischl MA, Chesney M. A randomized study of serial telephone call support to increase adherence and thereby improve virologic outcome in persons initiating antiretroviral therapy. J Infect Dis 2005; 192: 1398-406.</note>
</biblStruct>

<biblStruct xml:id="b37">
	<analytic>
		<title level="a" type="main" xml:id="_PkXjJes">Telephone support to improve antiretroviral medication adherence: a multisite, randomized controlled trial</title>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">R</forename><surname>Reynolds</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">A</forename><surname>Testa</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Su</surname></persName>
		</author>
		<idno type="DOI">10.1097/qai.0b013e3181582d54</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_nJZafSR">J Acquir Immune Defi c Syndr</title>
		<imprint>
			<biblScope unit="volume">47</biblScope>
			<biblScope unit="page" from="62" to="68" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Reynolds NR, Testa MA, Su M, et al. Telephone support to improve antiretroviral medication adherence: a multisite, randomized controlled trial. J Acquir Immune Defi c Syndr 2008; 47: 62-68.</note>
</biblStruct>

<biblStruct xml:id="b38">
	<analytic>
		<title level="a" type="main" xml:id="_nMQEVmy">Mortality of HIV-1infected patients in the fi rst year of antiretroviral therapy: comparison between low-income and high-income countries</title>
		<author>
			<persName><forename type="first">P</forename><surname>Braitstein</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">W</forename><surname>Brinkhof</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Dabis</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_d7fkAmF">Lancet</title>
		<imprint>
			<biblScope unit="volume">367</biblScope>
			<biblScope unit="page" from="817" to="824" />
			<date type="published" when="2006">2006</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Braitstein P, Brinkhof MW, Dabis F, et al. Mortality of HIV-1- infected patients in the fi rst year of antiretroviral therapy: comparison between low-income and high-income countries. Lancet 2006; 367: 817-24.</note>
</biblStruct>

<biblStruct xml:id="b39">
	<analytic>
		<title level="a" type="main" xml:id="_j3wa8FT">Kenya sets world fi rst with money transfers by mobile</title>
		<author>
			<persName><forename type="first">X</forename><surname>Rice</surname></persName>
		</author>
		<ptr target="http://www.guardian.co.uk/money/2007/mar/20/kenya.mobilephones" />
	</analytic>
	<monogr>
		<title level="j" xml:id="_sKnWYJb">The Guardian</title>
		<imprint>
			<date type="published" when="2007-03-20">March 20, 2007. Nov 4, 2010</date>
			<pubPlace>London</pubPlace>
		</imprint>
	</monogr>
	<note type="raw_reference">Rice X. Kenya sets world fi rst with money transfers by mobile. The Guardian (London) March 20, 2007: http://www.guardian.co. uk/money/2007/mar/20/kenya.mobilephones (accessed Nov 4, 2010).</note>
</biblStruct>

<biblStruct xml:id="b40">
	<analytic>
		<title level="a" type="main" xml:id="_qmbZ4T7">Impact of the Kenya post-election crisis on clinic attendance and medication adherence for HIV-infected children in western Kenya</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">C</forename><surname>Vreeman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">M</forename><surname>Nyandiko</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Sang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">S</forename><surname>Musick</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Braitstein</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">E</forename><surname>Wiehe</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_2JDsrX3">Confl Health</title>
		<imprint>
			<biblScope unit="volume">3</biblScope>
			<biblScope unit="page">5</biblScope>
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Vreeman RC, Nyandiko WM, Sang E, Musick BS, Braitstein P, Wiehe SE. Impact of the Kenya post-election crisis on clinic attendance and medication adherence for HIV-infected children in western Kenya. Confl Health 2009; 3: 5.</note>
</biblStruct>

<biblStruct xml:id="b41">
	<analytic>
		<title level="a" type="main" xml:id="_Kx3jk9X">Mobile phones: exceptional tools for HIV/AIDS, health, and crisis management</title>
		<author>
			<persName><forename type="first">R</forename><surname>Lester</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Karanja</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_b3PERXS">Lancet Infect Dis</title>
		<imprint>
			<biblScope unit="volume">8</biblScope>
			<biblScope unit="page" from="738" to="739" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Lester R, Karanja S. Mobile phones: exceptional tools for HIV/AIDS, health, and crisis management. Lancet Infect Dis 2008; 8: 738-39.</note>
</biblStruct>

<biblStruct xml:id="b42">
	<analytic>
		<title level="a" type="main" xml:id="_wTb2A6h">Patient support and education for promoting adherence to highly active antiretroviral therapy for HIV/AIDS</title>
		<author>
			<persName><forename type="first">S</forename><surname>Rueda</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Park-Wyllie</forename><surname>Ly</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">M</forename><surname>Bayoumi</surname></persName>
		</author>
		<idno type="DOI">10.1002/14651858.cd001442.pub2</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_FYasrxu">Cochrane Database Syst Rev</title>
		<imprint>
			<biblScope unit="volume">3</biblScope>
			<biblScope unit="page">1442</biblScope>
			<date type="published" when="2006">2006</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Rueda S, Park-Wyllie LY, Bayoumi AM, et al. Patient support and education for promoting adherence to highly active antiretroviral therapy for HIV/AIDS. Cochrane Database Syst Rev 2006; 3: CD001442.</note>
</biblStruct>

<biblStruct xml:id="b43">
	<analytic>
		<title level="a" type="main" xml:id="_BUzjpKK">Heterosexual HIV-1 transmission after initiation of antiretroviral therapy: a prospective cohort analysis</title>
		<author>
			<persName><forename type="first">D</forename><surname>Donnell</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">M</forename><surname>Baeten</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Kiarie</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_43xuenu">Lancet</title>
		<imprint>
			<biblScope unit="volume">375</biblScope>
			<biblScope unit="page" from="2092" to="2098" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Donnell D, Baeten JM, Kiarie J, et al. Heterosexual HIV-1 transmission after initiation of antiretroviral therapy: a prospective cohort analysis. Lancet 2010; 375: 2092-98.</note>
</biblStruct>

<biblStruct xml:id="b44">
	<analytic>
		<title level="a" type="main" xml:id="_V9Agu4D">Can antiretroviral therapy eliminate HIV transmission?</title>
		<author>
			<persName><forename type="first">De</forename><surname>Cock</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">M</forename><surname>Gilks</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">F</forename><surname>Lo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><forename type="middle">R</forename><surname>Guerma</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_6zVgwtU">Lancet</title>
		<imprint>
			<biblScope unit="volume">373</biblScope>
			<biblScope unit="page" from="7" to="9" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
	<note type="raw_reference">De Cock KM, Gilks CF, Lo YR, Guerma T. Can antiretroviral therapy eliminate HIV transmission? Lancet 2009; 373: 7-9.</note>
</biblStruct>

<biblStruct xml:id="b45">
	<analytic>
		<title level="a" type="main" xml:id="_GRsXDzu">Association of highly active antiretroviral therapy coverage, population viral load, and yearly new HIV diagnoses in British Columbia, Canada: a populationbased study</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">S</forename><surname>Montaner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><forename type="middle">D</forename><surname>Lima</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Barrios</surname></persName>
		</author>
		<idno type="DOI">10.1016/s0140-6736(10)60936-1</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_AjsuBDm">Lancet</title>
		<imprint>
			<biblScope unit="volume">376</biblScope>
			<biblScope unit="page" from="532" to="539" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Montaner JS, Lima VD, Barrios R, et al. Association of highly active antiretroviral therapy coverage, population viral load, and yearly new HIV diagnoses in British Columbia, Canada: a population- based study. Lancet 2010; 376: 532-39.</note>
</biblStruct>

<biblStruct xml:id="b46">
	<analytic>
		<title level="a" type="main" xml:id="_H4R9695">Home visits to improve adherence to highly active antiretroviral therapy: a randomized controlled trial</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">B</forename><surname>Williams</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">P</forename><surname>Fennie</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">A</forename><surname>Bova</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">D</forename><surname>Burgess</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">A</forename><surname>Danvers</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">D</forename><surname>Dieckhaus</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_WqTjA7G">J Acquir Immune Defi c Syndr</title>
		<imprint>
			<biblScope unit="volume">42</biblScope>
			<biblScope unit="page" from="314" to="321" />
			<date type="published" when="2006">2006</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Williams AB, Fennie KP, Bova CA, Burgess JD, Danvers KA, Dieckhaus KD. Home visits to improve adherence to highly active antiretroviral therapy: a randomized controlled trial. J Acquir Immune Defi c Syndr 2006; 42: 314-21.</note>
</biblStruct>

<biblStruct xml:id="b47">
	<analytic>
		<title level="a" type="main" xml:id="_UYfXCVg">From directly observed therapy to accompagnateurs: enhancing AIDS treatment outcomes in Haiti and in Boston</title>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">L</forename><surname>Behforouz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">E</forename><surname>Farmer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">S</forename><surname>Mukherjee</surname></persName>
		</author>
		<idno type="DOI">10.1086/421408</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_SpkdW2g">Clin Infect Dis</title>
		<imprint>
			<biblScope unit="volume">38</biblScope>
			<biblScope unit="issue">suppl 5</biblScope>
			<biblScope unit="page" from="429" to="436" />
			<date type="published" when="2004">2004</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Behforouz HL, Farmer PE, Mukherjee JS. From directly observed therapy to accompagnateurs: enhancing AIDS treatment outcomes in Haiti and in Boston. Clin Infect Dis 2004; 38 (suppl 5): S429-36.</note>
</biblStruct>

<biblStruct xml:id="b48">
	<analytic>
		<title level="a" type="main" xml:id="_fXgQsVy">Explaining adherence success in sub-Saharan Africa: an ethnographic study</title>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">C</forename><surname>Ware</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Idoko</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Kaaya</surname></persName>
		</author>
		<idno type="DOI">10.1371/journal.pmed.1000011</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_REUaTDA">PLoS Med</title>
		<imprint>
			<biblScope unit="volume">6</biblScope>
			<biblScope unit="page">e11</biblScope>
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Ware NC, Idoko J, Kaaya S, et al. Explaining adherence success in sub-Saharan Africa: an ethnographic study. PLoS Med 2009; 6: e11.</note>
</biblStruct>

<biblStruct xml:id="b49">
	<analytic>
		<title level="a" type="main" xml:id="_7CRBYzm">Adherence to antiretroviral therapy in sub-Saharan Africa and North America: a meta-analysis</title>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">J</forename><surname>Mills</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">B</forename><surname>Nachega</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Buchan</surname></persName>
		</author>
		<idno type="DOI">10.1001/jama.296.6.679</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_AwQdRgQ">JAMA</title>
		<imprint>
			<biblScope unit="volume">296</biblScope>
			<biblScope unit="page" from="679" to="690" />
			<date type="published" when="2006">2006</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Mills EJ, Nachega JB, Buchan I, et al. Adherence to antiretroviral therapy in sub-Saharan Africa and North America: a meta-analysis. JAMA 2006; 296: 679-90.</note>
</biblStruct>

<biblStruct xml:id="b50">
	<analytic>
		<title level="a" type="main" xml:id="_qUVV6ax">Current trends in Internet-and cell phone-based HIV prevention and intervention programs</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">L</forename><surname>Ybarra</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">S</forename><surname>Bull</surname></persName>
		</author>
		<idno type="DOI">10.1007/s11904-007-0029-2</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_3Pwq7mZ">Curr HIV/AIDS Rep</title>
		<imprint>
			<biblScope unit="volume">4</biblScope>
			<biblScope unit="page" from="201" to="207" />
			<date type="published" when="2007">2007</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Ybarra ML, Bull SS. Current trends in Internet-and cell phone-based HIV prevention and intervention programs. Curr HIV/AIDS Rep 2007; 4: 201-07.</note>
</biblStruct>

				</listBibl>
			</div>
		</back>
	</text>
</TEI>
